Roth Capital Predicts Beyond Air FY2029 Earnings

Beyond Air, Inc. (NASDAQ:XAIR) – Investment analysts at Roth Capital issued their FY2029 earnings per share (EPS) estimates for shares of Beyond Air in a report released on Tuesday, February 11th. Roth Capital analyst J. Wittes forecasts that the company will post earnings of $0.06 per share for the year. The consensus estimate for Beyond Air’s current full-year earnings is ($0.87) per share.

Beyond Air (NASDAQ:XAIR) last announced its earnings results on Monday, February 10th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.09. Beyond Air had a negative net margin of 2,369.17% and a negative return on equity of 227.29%. During the same period in the prior year, the firm earned ($0.50) earnings per share.

Beyond Air Stock Down 0.2 %

Beyond Air stock opened at $0.37 on Thursday. Beyond Air has a 1-year low of $0.30 and a 1-year high of $2.12. The business has a fifty day moving average price of $0.41 and a 200-day moving average price of $0.43. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.76 and a quick ratio of 5.38. The stock has a market capitalization of $28.06 million, a price-to-earnings ratio of -0.26 and a beta of -0.15.

Institutional Investors Weigh In On Beyond Air

Several institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its holdings in shares of Beyond Air by 81.0% during the fourth quarter. Geode Capital Management LLC now owns 562,713 shares of the company’s stock valued at $202,000 after acquiring an additional 251,823 shares in the last quarter. Baldwin Wealth Partners LLC MA grew its position in Beyond Air by 721.3% during the 4th quarter. Baldwin Wealth Partners LLC MA now owns 308,000 shares of the company’s stock worth $110,000 after purchasing an additional 270,500 shares during the last quarter. Finally, Soros Fund Management LLC acquired a new position in Beyond Air during the 3rd quarter valued at approximately $573,000. Institutional investors and hedge funds own 31.50% of the company’s stock.

About Beyond Air

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.